Research
Hormonal
Preoperative and postoperative pharmacotherapy with GLP-1 agonists (semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) significantly enhances weight loss outcomes and reduces weight regain after bariatric surgery.
Using GLP-1 or dual agonists like semaglutide or tirzepatide before or after bariatric surgery can significantly boost weight loss results and prevent the common problem of weight regain, offering a powerful tool for long-term metabolic health.
GoodSupportsHIGH confidence
Pharmacotherapy using semaglutide and tirzepatide is effective both before and after surgery, reducing the frequency of weight loss [regain].
Why this rating
Supported by RCTs (STEP, SURMOUNT, SELECT) and registry data.
Source
Current trends in bariatric surgery
А. Е. Неймарк et al. · Russian surgical journal · 2025
DOI 10.18705/3034-7270-2025-1-2-103-111
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Laparoscopic sleeve gastrectomy (LSG) provides 60–70% excess weight loss and 50–60% type 2 diabetes remission at 5–7 years, with efficacy comparable to Roux-en-Y gastric bypass (RYGB) and superior safety for super-obese patients (BMI > 60).Good
- Standardized multidisciplinary care and ERAS protocols reduce postoperative complications to ~1% and shorten hospital stays, improving overall safety and long-term outcomes.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →